US Patent 10590085 Heterocyclic amides as kinase inhibitors
Patent 10590085 was granted and assigned to GlaxoSmithKline on March, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 11 Dec, 2023
Golden AI
Edits made to:
Article (+62 characters)
Article
Patent abstract
Disclosed are compounds having the formula (I):
Edits on 4 Oct, 2023
Golden AI
Edits made to:
Infobox (+13 properties)
Infobox
Patent Inventor Names
Alain Claude-Marie Daugan0
Bryan W. King0
Clark A. Sehon0
David Duff Wisnoski0
Deepak Bandyopadhyay0
Frederic G. Donche0
Gemma Victoria White0
Jae U. Jeong0
Niall Andrew Anderson0
Nicolas Eric Faucher0
Nicolas S. George0
Patrick M. Eidam0
Philip Anthony Harris0
Edits on 5 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 3 Nov, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 9 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 2 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10590085 Heterocyclic amides as kinase inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10590085
Date of patent
March 17, 2020
Patent application number
15575235
Date Filed
May 19, 2016
Patent primary examiner
Find more entities like US Patent 10590085 Heterocyclic amides as kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.